secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2022-05-03T23:59:59+00:00
Accession:  0001384101-22-000068
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte Q1 revenue up 85% to $67.8M; net loss narrows 65%
----------------------------------------------------------

- Total revenue $67.8M, +85% YoY; test volumes 23,245, +61% YoY.
- Testing revenue $56.0M (+69%); Biopharma and other $8.8M (vs $0.6M); product revenue $3.0M (-3%).
- GAAP net loss $14.5M, improved 65%; diluted EPS loss $0.20, improved 70%.
- Non-GAAP gross margin 65%, roughly flat; cash $163.6M at quarter-end.
- Business highlights: expanded Percepta data at ATS, three AUA abstracts, launch of Biopharma Atlas.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410122000068/0001384101-22-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410122000068/vcyt-20220503.htm
  HTML page:      https://secwatch.observer/filing/0001384101-22-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer